HSPG2 and ischemia: A potential means of overcoming limitations of angiogenic therapy, or stimulation of new blood vessel growth to treat ischemia using pro‐angiogenic factors, is through bio‐inspired approaches, in particular by mimicking the natural role of the ECM and GAGs in growth factor binding and signaling.[6] One such example is demonstrated in the current study, where a recombinantly expressed C‐terminal fragment rDV of the proteoglycan perlecan is demonstrated to promote angiogenesis and vascularization of implanted biomaterials via GAG dependent growth factor signaling.